On June 10, 2021, a group of patients and families affected by Arginase 1 Deficiency (ARG1-D) participated in a one-hour virtual listening session with officials from the Food and Drug Administration (FDA). The session enabled those with ARG1-D and their caregivers to  share their experiences, perspectives, needs, goals with officials from across the agency.

• Difficulties obtaining a correct diagnosis
• Symptoms and experiences related to living with ARG1-D
• The impact or the condition on daily functioning and quality of life
• Experiences and challenges with existing treatments and the current state of disease management
• The need for disease awareness, improved care guidelines, and better treatment options